Rickenbach Josef Von Purchases 15,950 Shares of Rein Therapeutics (NASDAQ:RNTX) Stock

Rein Therapeutics Inc. (NASDAQ:RNTX) Director Rickenbach Josef Von bought 15,950 shares of the business’s stock in a transaction dated Friday, May 22nd. The stock was acquired at an average cost of $1.05 per share, for a total transaction of $16,747.50. Following the completion of the acquisition, the director directly owned 34,824 shares in the company, valued at approximately $36,565.20. This trade represents a 84.51% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Rein Therapeutics Trading Up 4.7%

Shares of Rein Therapeutics stock traded up $0.05 during trading on Thursday, reaching $1.11. The company’s stock had a trading volume of 425,172 shares, compared to its average volume of 1,491,003. The company has a 50-day moving average price of $1.33 and a two-hundred day moving average price of $1.31. The firm has a market cap of $94.95 million, a PE ratio of -0.58 and a beta of 1.42. Rein Therapeutics Inc. has a fifty-two week low of $0.95 and a fifty-two week high of $2.18.

Rein Therapeutics (NASDAQ:RNTX) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.30. On average, analysts predict that Rein Therapeutics Inc. will post -1.63 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of Rein Therapeutics to a “sell” rating in a research report on Saturday, May 16th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Rein Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $8.00.

Hedge Funds Weigh In On Rein Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Sigma Planning Corp boosted its position in shares of Rein Therapeutics by 41.0% during the 1st quarter. Sigma Planning Corp now owns 348,677 shares of the company’s stock worth $453,000 after purchasing an additional 101,400 shares in the last quarter. Chicago Partners Investment Group LLC boosted its position in shares of Rein Therapeutics by 32.2% during the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock worth $53,000 after purchasing an additional 10,000 shares in the last quarter. State Street Corp boosted its position in shares of Rein Therapeutics by 374.3% during the 4th quarter. State Street Corp now owns 75,904 shares of the company’s stock worth $88,000 after purchasing an additional 59,900 shares in the last quarter. Voss Capital LP boosted its position in shares of Rein Therapeutics by 59.2% during the 4th quarter. Voss Capital LP now owns 4,243,969 shares of the company’s stock worth $4,923,000 after purchasing an additional 1,577,437 shares in the last quarter. Finally, Gagnon Securities LLC boosted its position in shares of Rein Therapeutics by 5.0% during the 4th quarter. Gagnon Securities LLC now owns 240,220 shares of the company’s stock worth $279,000 after purchasing an additional 11,528 shares in the last quarter. 90.89% of the stock is currently owned by hedge funds and other institutional investors.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.